S0758

Sulfaphenazole

Name: Sulfaphenazole
Brand: SIGMA

≥98%, CYP2C9 inhibitor, powder

Synonyme(s) :

4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Toutes les photos(2)

About This Item

Formule empirique (notation de Hill) :

C₁₅H₁₄N₄O₂S

Numéro CAS:

526-08-9

Poids moléculaire :

314.36

NACRES:

NA.77

PubChem Substance ID:

24278198

UNSPSC Code:

12352204

EC Number:

208-384-3

MDL number:

MFCD00057226

Nom du produit

Sulfaphenazole, ≥98%

InChI key

QWCJHSGMANYXCW-UHFFFAOYSA-N

InChI

1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3

assay

≥98%

form

powder

solubility

ethanol: 25 mg/mL, clear, colorless to yellow

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

Sulfaphenazole has been used as a positive control to inhibit cytochrome P450 2C9 (cyp2c9) to quantify Rhodiola rosea inhibition. It has also been used as cytochrome P450 2C9 (cyp2c9) inhibitor in endothelial cells and microsomal preparations.

Biochem/physiol Actions

Antibacterial. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release.

Classe de stockage

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

0000508715

0000436070

0000368519

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform

Moraes CB, et al.

SLAS discovery, 24(3), 346-361 (2019)

Altered purinergic signaling in uridine adenosine tetraphosphate-induced coronary relaxation in swine with metabolic derangement

Zhou Z, et al.

Purinergic Signaling, 13(3), 319-329 (2017)

KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin.

Vienna E Brunt et al.

The Journal of physiology, 590(15), 3523-3534 (2012-06-08)

While it is accepted that NO is responsible for ∼60% of the plateau in cutaneous thermal hyperaemia, a large portion of the response remains unknown. We sought to determine whether the remaining ∼40% could be attributed to EDHF-mediated activation of

In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.

Simon Lucas et al.

Journal of medicinal chemistry, 51(24), 8077-8087 (2008-12-04)

Pyridine substituted naphthalenes (e.g., I-III) constitute a class of potent inhibitors of aldosterone synthase (CYP11B2). To overcome the unwanted inhibition of the hepatic enzyme CYP1A2, we aimed at reducing the number of aromatic carbons of these molecules because aromaticity has

Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.

Zhiping Jin et al.

Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)

Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique